Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy

Molecular radiotherapy using 177Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive u...

Full description

Bibliographic Details
Authors: O’Neill, Edward, Kersemans, Veerle, Allen, P. Danny, Terry, Samantha Y. A., Baguña Torres, Júlia, Mosley, Michael, Smart, Sean, Lee, Boon Quan, Falzone, Nadia, Vallis, Katherine A., Konijnenberg, Mark W., Jong, Marion de, Nonnekens, Julie, Cornelissen, Bart
Format: article
Status:Published version
Publication Date:2020
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/419932
Online Access:http://hdl.handle.net/10261/419932
Access Level:Open access
Keyword:177Lu-DOTATATE
γH2AX
SPECT
DNA damage
Neuroendocrine cancer
Description
Summary:Molecular radiotherapy using 177Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive uptake on octreotide-based PET/SPECT imaging, treatment is usually administered as a standard dose and number of cycles without adjustment for peptide uptake, dosimetry, or radiobiologic and DNA damage effects in the tumor. Here, we visualized and quantified the extent of DNA damage response after 177Lu-DOTATATE therapy using SPECT imaging with 111In-anti-γH2AX-TAT. This work was a proof-of-principle study of this in vivo noninvasive biodosimeter with β-emitting therapeutic radiopharmaceuticals.

Similar Items